Astrazeneca PLC Forecasted to Post Q3 2016 Earnings of $0.47 Per Share (AZN)
Astrazeneca PLC (NYSE:AZN) – Analysts at Leerink Swann lowered their Q3 2016 EPS estimates for shares of Astrazeneca PLC in a research note issued on Thursday. Leerink Swann analyst S. Fernandez now expects that the firm will post earnings per share of $0.47 for the quarter, down from their previous estimate of $0.56. Leerink Swann has a “Hold” rating and a $35.00 price objective on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.06 EPS.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same quarter last year, the business earned $1.21 earnings per share. Astrazeneca PLC’s revenue was down 4.0% compared to the same quarter last year.
AZN has been the topic of a number of other reports. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Bank of America Corp. set a $41.40 target price on shares of Astrazeneca PLC and gave the company a “buy” rating in a research note on Thursday, September 8th. Piper Jaffray Cos. assumed coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They issued an “overweight” rating on the stock. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday. Finally, TheStreet upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.06 on Monday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The firm has a market cap of $81.11 billion, a price-to-earnings ratio of 36.64 and a beta of 0.75. The firm has a 50 day moving average of $33.19 and a 200 day moving average of $30.86.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were paid a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is 78.29%.
Several large investors have recently bought and sold shares of the company. TIAA CREF Investment Management LLC increased its stake in Astrazeneca PLC by 45.2% in the first quarter. TIAA CREF Investment Management LLC now owns 398,366 shares of the company’s stock worth $11,218,000 after buying an additional 124,066 shares during the period. Teachers Advisors Inc. increased its stake in Astrazeneca PLC by 595.6% in the first quarter. Teachers Advisors Inc. now owns 510,989 shares of the company’s stock worth $14,389,000 after buying an additional 437,531 shares during the period. Franklin Resources Inc. increased its stake in Astrazeneca PLC by 89.8% in the first quarter. Franklin Resources Inc. now owns 2,026,200 shares of the company’s stock worth $57,058,000 after buying an additional 958,821 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Astrazeneca PLC by 118.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 11,230 shares of the company’s stock worth $316,000 after buying an additional 6,081 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock worth $65,485,000 after buying an additional 6,027 shares during the period. 11.39% of the stock is owned by institutional investors and hedge funds.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.